PPARG and Hepatic fibrosis: We wondered whether the selective activation of PPARγ in liver macrophages with a low dose (1/4 of conventional dose) of GW1929 that was linked to DGNS could be effective in stimulating a selective M2 anti-inflammatory macrophage phenotype and boosting macrophage-driven liver fibrosis resolution.